Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Adicet Bio (ACET)
NASDAQ:ACET
Holding ACET?
Track your performance easily
ACET Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.81 - $3.77
Previous Close$0.91
Volume632.17K
Average Volume (3M)597.57K
Market Cap
$70.89M
Enterprise Value-$112.98M
Total Cash (Recent Filing)$202.06M
Total Debt (Recent Filing)$18.20M
Price to Earnings (P/E)―
Beta1.28
Next Earnings
Mar 12, 2025EPS Estimate
-$0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.71
Shares Outstanding82,400,960
10 Day Avg. Volume699,131
30 Day Avg. Volume597,570
Standard Deviation0.26
R-Squared0.14
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.35
Price to Sales (P/S)99.29
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.62
Enterprise Value/Gross Profit-158.23
Enterprise Value/Ebitda1.01
Forecast
1Y Price Target
$5.50Price Target Upside504.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
Adicet Bio News
PremiumCompany Announcements
Adicet Bio Advances with Phase 1 Trial of ADI-270
PremiumCompany Announcements
Adicet Bio Clears Debts with Banc of California
PremiumCompany Announcements
Adicet Bio Reports Q3 2024 Results and Clinical ProgressPremiumCompany Announcements
Adicet Bio Advances Cancer and Autoimmune Trials
Bulls Say, Bears Say
Bulls Say
Clinical DataADI-001 showed approximately 8.5 times higher tissue penetration than historical data with Yescarta.
Clinical TrialsAdicet announced that the first patient has been dosed in the multi-center, open-label Phase 1 clinical trial evaluating ADI-270.
Regulatory ApprovalADI-270 has been granted Fast Track Designation by the FDA for potential treatment of patients with metastatic/advanced clear cell renal cell carcinoma.
Bears Say
Clinical DevelopmentThe company has discontinued enrollment for its lead program and currently has no clinical data available for new potential indications.
Financial PerformanceFor FY24, the EPS estimate is being decreased, indicating potential financial challenges.
Therapeutic OptionsThere is no confirmation yet that engineered gamma-delta T cells offer a superior therapeutic option over current standards.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ACET FAQ
What was Adicet Bio’s price range in the past 12 months?
Adicet Bio lowest stock price was $0.81 and its highest was $3.77 in the past 12 months.
What is Adicet Bio’s market cap?
Currently, no data Available
When is Adicet Bio’s upcoming earnings report date?
Adicet Bio’s upcoming earnings report date is Mar 12, 2025 which is in 81 days.
How were Adicet Bio’s earnings last quarter?
Adicet Bio released its earnings results on Nov 06, 2024. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$0.341 by $0.001.
Is Adicet Bio overvalued?
According to Wall Street analysts Adicet Bio’s price is currently Undervalued.
Does Adicet Bio pay dividends?
Adicet Bio does not currently pay dividends.
What is Adicet Bio’s EPS estimate?
Adicet Bio’s EPS estimate is -$0.35.
How many shares outstanding does Adicet Bio have?
Adicet Bio has 82,400,960 shares outstanding.
What happened to Adicet Bio’s price movement after its last earnings report?
Adicet Bio reported an EPS of -$0.34 in its last earnings report, beating expectations of -$0.341. Following the earnings report the stock price went up 2.308%.
Which hedge fund is a major shareholder of Adicet Bio?
Among the largest hedge funds holding Adicet Bio’s share is RA Capital Management. It holds Adicet Bio’s shares valued at 11M.
---
Adicet Bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.50 (504.40% Upside)
$5.50 (504.40% Upside)
Blogger Sentiment
Bullish
ACET Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 519.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.67%
12-Months-Change
Fundamentals
Return on Equity
-58.04%
Trailing 12-Months
Asset Growth
5.45%
Trailing 12-Months
Company Description
Adicet Bio
resTORbio, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development and commercialization of medicines for aging-related diseases and conditions. It offers an immunotherapy under the TORC1 program. The company was founded by Chen Schor and Joan Mannick on July 5, 2016 and is headquartered in Boston, MA.
---
ACET Stock 12 Month Forecast
Average Price Target
$5.50
▲(504.40% Upside)
Technical Analysis
Best Analysts Covering ACET
1 Year
1 Year Success Rate
4/10 ratings generated profit
1 Year Average Return
-11.94%
reiterated a buy rating 3 months ago
Copying John Newman's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -11.94% per trade.
---